Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pregabalin - Pfizer

Drug Profile

Pregabalin - Pfizer

Alternative Names: CI 1008; Isobutylgaba; Lyrica; PD 144723

Latest Information Update: 25 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwestern University
  • Developer Eisai Co Ltd; Pfizer
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia
  • Phase III Tonic-clonic epilepsy
  • Discontinued Pain; Postoperative pain; Restless legs syndrome

Most Recent Events

  • 22 Aug 2019 Pfizer completes a phase III trial in Partial epilepsies (Adjunctive treatment, In children, In infants) and Tonic-clonic epilepsy (Adjunctive treatment, In adolescents, In adults, In children) in the US, Belarus, Belgium,Bosnia and Herzegovina, Bulgaria, China, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, South Korea, Lebanon, Malaysia, Montenegro, Philippines, Poland, Romania, Russia, Serbia, Singapore, Slovakia, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom (PO) (NCT01463306) (EudraCT2011-001412-65)
  • 27 May 2019 Top-line adverse events and efficacy data from a phase III trial in primary generalized Tonic-clonic epilepsy released by Pfizer (NCT01747915)
  • 20 Feb 2019 Pfizer completes a phase III trial in Tonic-clonic epilepsy (Adjunctive treatment, In children, In adolescents, In adults) in USA, Argentina, Austria, Belarus, Bosnia-Herzegovina, Bulgaria, China, Croatia, Denmark, France, Greece, Hungary, India, South Korea, Lebanon, Malaysia, Montenegro, Philippines, Poland, Romania, Russia, Serbia, Slovakia, Spain, Turkey, Ukraine, United Kingdom, Lithuania, the Netherlands, Estonia, Belgium, Germany (NCT01747915)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top